Bioton has an agreement with Biotts to develop a patch for use in diabetes

Biotts and Bioton have signed a cooperation agreement under which the listed company will provide insulin for patches enabling the application of drugs through the skin thanks to the transdermal system from Biotts. After the Proof of Concept stage, the biotech will develop a comprehensive product, ready to be introduced to the global pharmaceutical market, the companies said. Transdermal insulin developed by Biotts in cooperation with Bioton will be a breakthrough on the market of drugs used in diabetes, it was emphasized.

“The Wrocław-based biopharmaceutical company Biotts is one of the global pioneers of innovative carriers enabling the application of drugs through the skin using the transdermal method (through the skin, in the form of patches, without injections) and increasing the bioavailability of active substances. Now Biotts plans to use breakthrough technology in the application of commonly used antidiabetic drugs – in this way it will not only reduce the negative side effects of oral drugs and injections, but also reduce the doses and increase the effectiveness of the administered pharmaceuticals. For this purpose, Biotts concluded a PoC (Proof of Concept) cooperation agreement with the listed Bioton. Bioton is one of eight global producers of recombinant human insulin on a commercial scale and a leader in insulin production in Poland. […] The goal is clear: in the near future, Biotts and Bioton’s solution is to revolutionize the everyday life of people with diabetes, replacing oral medications, insulin pumps or painful injections,” we read in the release.

“While still under investigation, early results support the effectiveness of our patented MTC-Y universal transdermal carrier system. Insulin penetrates the skin almost instantly and reaches the therapeutic window within minutes. It then remains constant for up to 72 hours, offering patients the opportunity to replace several injections with one simple patch. This highlights two key advantages of our MTC-Y technology: it is completely non-invasive and therefore patient-friendly and it ensures a constant level of insulin in the blood plasma for a longer period of time. This makes the Biotts transdermal carrier system truly unique,” added Biotts CTO and co-founder Paweł Biernat, quoted in the material.

By 2027, Biotts plans to create a finished product in the form of patches, ready for introduction to the global pharmaceutical market. The American branch of the company – Biotts US – is also involved in the development and financing of this project, it was also announced.

“Cooperation between two Polish companies is extremely important. Firstly, it shows the innovation that continues in the Polish biotechnology and medical technology industry. Most importantly, transdermal technology gives our patients a wider choice of drug delivery systems. Insulin is an excellent first candidate for this technology, and Bioton has extensive experience in this area. We have been providing insulin to people requiring insulin treatment for over 20 years and understand the barriers to insulin treatment and patient needs. We also see the potential to use this technology in products that are in the development phase,” said Bioton CEO Jeremy Launders.

According to a report by the International Diabetes Federation (IDF), the number of people with diabetes aged 20-79 years was 537 million in 2021. It is estimated that by 2030 this number will reach 643 million and by 2045 783 million people. At the same time, the increasing occurrence of chronic diseases in patients and the need to create alternative methods of drug administration are driving the dynamic development of transdermal technologies. According to the latest report by The Insight Partners 2023, the global market for transdermal drug delivery systems will grow from USD 37.23 billion in 2022 to USD 51.94 billion by 2030, it was also reported.

Biotts is a biopharmaceutical company from Wrocław, established in 2018. Biotts scientists develop proprietary drug transport technologies and drug recipes in the area of diabetes and oncology. The Biotts team of technologists has developed an original technology for obtaining a universal transdermal therapeutic system.

Bioton is a Polish biotechnology company engaged in the production of medicines. Founded in 1989, it has been operating as a joint-stock company since 2004 and has been listed on the Warsaw Stock Exchange since 2005.


Our privacy policy